These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 32298597)
41. S4646 polymorphism in CYP19A1 gene is associated with the efficacy of hormone therapy in early breast cancer. Shao X; Cai J; Zheng Y; Wang J; Feng J; Huang Y; Shi L; Chen Z; Guo Y; Wang X Int J Clin Exp Pathol; 2015; 8(5):5309-17. PubMed ID: 26191232 [TBL] [Abstract][Full Text] [Related]
42. Impact of Maddin N; Husin A; Gan SH; Aziz BA; Ankathil R Oncol Ther; 2016; 4(2):303-314. PubMed ID: 28261657 [TBL] [Abstract][Full Text] [Related]
43. Association of Cytotoxic T-lymphocyte Antigen-4 Polymorphisms with Malignant Bone Tumor Risk: A Meta-analysis. Zhang C; Hou WH; Ding XX; Wang X; Zhao H; Han XW; Wang WJ Asian Pac J Cancer Prev; 2016; 17(8):3785-91. PubMed ID: 27644617 [TBL] [Abstract][Full Text] [Related]
44. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. An SH; Chang BC; Lee KE; Gwak HS Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945 [TBL] [Abstract][Full Text] [Related]
46. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study. Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889 [TBL] [Abstract][Full Text] [Related]
47. Single nucleotide polymorphism of hsa-miR-124a affects risk and prognosis of osteosarcoma. Shi ZW; Wang JL; Zhao N; Guan Y; He W Cancer Biomark; 2016 Jun; 17(2):249-57. PubMed ID: 27540978 [TBL] [Abstract][Full Text] [Related]
48. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Long JR; Egan KM; Dunning L; Shu XO; Cai Q; Cai H; Dai Q; Holtzman J; Gao YT; Zheng W Pharmacogenet Genomics; 2006 Apr; 16(4):237-43. PubMed ID: 16538170 [TBL] [Abstract][Full Text] [Related]
49. Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia. Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Biswas NR; Gupta YK Pharmacol Res; 2017 Jun; 120():138-145. PubMed ID: 28330783 [TBL] [Abstract][Full Text] [Related]
50. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Lang F; Eichelbaum M; Strandberg T Am J Pharmacogenomics; 2005; 5(3):191-5. PubMed ID: 15952872 [TBL] [Abstract][Full Text] [Related]
51. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population. Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143 [TBL] [Abstract][Full Text] [Related]
52. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Staatz CE; Goodman LK; Tett SE Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406 [TBL] [Abstract][Full Text] [Related]
53. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level. Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154 [TBL] [Abstract][Full Text] [Related]
54. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma. Zhang Q; Lv LY; Li BJ; Zhang J; Wei F Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354 [TBL] [Abstract][Full Text] [Related]
55. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907 [TBL] [Abstract][Full Text] [Related]
56. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors. Yang LM; Li XH; Bao CF Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281 [TBL] [Abstract][Full Text] [Related]
57. Influence of CYP3A5 6986A > G and ABCB1 3435C > T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Sy SK; Singh RP; Shilbayeh S; Zmeili R; Conrado D; Derendorf H Clin Pharmacol Drug Dev; 2013 Jan; 2(1):67-78. PubMed ID: 27121561 [TBL] [Abstract][Full Text] [Related]
58. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181 [TBL] [Abstract][Full Text] [Related]
59. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy. Yang J; Wang ZG; Cai HQ; Li YC; Xu YL Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708 [TBL] [Abstract][Full Text] [Related]